Remedium Healthcare Products announces the launch of NuVeria Labs' Sacral Silicone Dressing on Amazon, setting a new standard in accessible, advanced wound
BOSTON, Oct. 16, 2023 /PRNewswire/ -- Remedium Bio is excited to announce that the company has been selected as a finalist for the in-person pitch competition at the upcoming Boehringer Ingelheim (BI) External Innovation Day. This year's BI Innovation Day will take place on Oct 26th at the Boehringer Ingelheim Biopharmaceuticals Business Unit headquarters at Fremont, California. Remedium will present its Prometheus™ dose adjustable gene therapy platform technology – a first-in-class system, which enables ultra-low-cost delivery of virtually any subcutaneously administered biologic, as a single injection adjustable dose gene therapy. The company will also highlight progress on its pipeline candidate for the treatment of Type 2 Diabetes and Obesity RMD1202 – a single injection, adjustable dose, subcutaneously administered GLP-1 Receptor Agonist gene therapy.
Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), and Exothera S.A., a full-service CDMO specialized in gene therapy, vaccines, and oncolytic viruses, entered a collaboration agreement to demonstrate the industrialization potential of Remedium’s AAV2-FGF18.